Showing results (101-110 of 217) with videos related to

Sort By:
Pageof 22
Rheumatology (Oxford, England)|May 6, 2021
Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosusRichard A Furie, Ian N Bruce, Thomas Dörner, et al.
The Lancet. Rheumatology|April 5, 2021
The role of antirheumatics in patients with COVID-19Christoffer B Nissen, Savino Sciascia, Danieli de Andrade, et al.
BMJ Open|March 23, 2019
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocolY K Onno Teng, Ian N Bruce, Betty Diamond, et al.
Annals of the Rheumatic Diseases|October 16, 2012
Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general populationSuzanne M M Verstappen, Mark Lunt, Robert N Luben, et al.
Annals of the Rheumatic Diseases|February 2, 2025
Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controlsZahi Touma, Ian N Bruce, Richard Furie, et al.
Annals of the Rheumatic Diseases|March 21, 2013
N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR)Hoda Mirjafari, Paul Welsh, Suzanne M M Verstappen, et al.
Clinical Proteomics|July 29, 2023
Proteomic analysis identifies subgroups of patients with active systemic lupus erythematosusKevin Y C Su, John A Reynolds, Rachel Reed, et al.
RMD Open|January 4, 2023
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk toleranceGwenda Simons, Ellen M Janssen, Jorien Veldwijk, et al.
Rheumatology (Oxford, England)|June 29, 2022
Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprineJohn A Reynolds, Mary Gayed, Munther A Khamashta, et al.
Arthritis and Rheumatism|August 1, 2007
Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosusKathleen McElhone, Janice Abbott, Joanna Shelmerdine, et al.
Pageof 22